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Background: Burkholderia cepacia complex (Bcc) infections in cystic fibrosis (CF) patients are associated with decline in 
lung function and reduced survival. The potential transmissibility of Bcc among CF patients has been reported, indicating that 
strict segregation of CF patients with Bcc is crucial. 
Aims: To standardize the PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) assay in order 
to identify Bcc species and to establish the prevalence of Bcc species and their susceptibility profile among CF patients seen 
at the Hospital de Clínicas de Porto Alegre (HCPA). 
Methods: The classification of the clinical isolates recovered from respiratory tract specimens of CF patients as Bcc was 
achieved using the API-20NE® phenotypic commercial system. The identification of the Bcc species was performed using 
PCR-RFLP. The antimicrobial disc diffusion susceptibility testing was performed according to the CLSI (2006). 
Results: API-20NE® was able to identify Bcc isolates (244 specimens), such as B. cepacia, indicating that it was not able to 
distinguish among the Bcc species. The PCR-RFLP molecular method discriminated the eight reference Bcc species, thus 
validating the method for clinical isolates. Bcc prevalence determined by PCR-RFLP was 10.6% (26/244). The molecular 
analysis identified B. cenocepacia in 53.8% (14/26) of infected patients, B. multivorans in 15.4% (4/26), and B. vietnamiensis 
and B. ambifaria in 7.7% (2/26). The antibiotic resistance profile was variable among Bcc species. 
Conclusions: The PCR-RFLP method was validated for the identification of Bcc species. B. cenocepacia proved to be the 
most prevalent species among the CF patients seen at the HCPA. 
 




Introdução: Infecções por bactérias do complexo Burkholderia cepacia (CBC) em pacientes com fibrose cística (FC) estão 
associadas a declínio da função pulmonar e diminuição da sobrevida. O potencial de transmissibilidade de CBC entre paci-
entes com FC é uma realidade, tornando-se importante a estrita segregação dos pacientes infectados. 
Objetivos: Padronizar a técnica de PCR-RFLP (reação em cadeia da polimerase seguida de clivagem com enzimas de 
restrição) para diferenciação das espécies de CBC e estabelecer a prevalência dessas espécies e seus perfis de sensibili-
dade em pacientes com FC atendidos no Hospital de Clínicas de Porto Alegre (HCPA). 
Métodos: A identificação dos isolados clínicos do trato respiratório de pacientes com FC como CBC foi feita pelo sistema de 
identificação fenotípica comercial API-20NE®. A diferenciação das espécies de CBC foi realizada por PCR-RFLP, e o teste 
de suscetibilidade aos antimicrobianos por disco-difusão foi realizado de acordo com o CLSI (2006). 
Resultados: O sistema API-20NE® identificou todos os isolados do CBC (244 amostras) como B. cepacia, indicando clara-
mente que não distingue as espécies do complexo. O método molecular de PCR-RFLP discriminou as oito espécies de 
referência de CBC, validando o método para isolados clínicos. A prevalência de CBC por PCR-RFLP foi de 10,6% (26/244). 
A análise molecular apontou B. cenocepacia colonizando em 53,8% (14/26) dos pacientes infectados, B. multivorans em 
15,4% (4/26) e B. vietnamiensis e B. ambifaria em 7,7% (2/26). O perfil de resistência entre as espécies de CBC para os 
antibióticos testados foi variado. 
Conclusão: Foi validada a aplicação do método molecular PCR-RFLP para identificar espécies de CBC, e B. cenocepacia 
foi a espécie mais prevalente entre os pacientes fibrocísticos atendidos no HCPA. 
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Cystic fibrosis (CF) is the most common le-
thal genetic disease among Caucasians (1,2). 
CF causes a systemic disease which affects 
mainly the respiratory tract leading to chronic 
infection of the airways. There is a variety of 
bacterial species involved in the CF respiratory 
infection, but Staphylococcus aureus, Pseudo-
monas aeruginosa, and Burkholderia cepacia 
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complex (Bcc) are the main microorganisms 
associated with airway infections (3,4). Bcc con-
sists of a group of phenotypically and phyloge-
netically closely related but distinct bacterial 
species (previously termed genomovars) as 
follows: Burkholderia cepacia (genomovar I), 
Burkholderia multivorans (genomovar II), 
Burkholderia cenocepacia (genomovar III with 
subgroups IIIA, IIIB, IIIC and IIID), Burkholderia 
stabilis (genomovar IV), Burkholderia viet-
namiensis (genomovar V), Burkholderia dolosa 
(genomovar VI), Burkholderia ambifaria (geno-
movar VII), Burkholderia anthina (genomovar 
VIII), Burkholderia pyrrocinia (genomovar IX), 
and Burkholderia ubonensis (genomovar X). A 
novel species is under process of being formally 
designated according to multilocus sequence 
typing (5). 
Bcc infections are usually associated with a 
decline in lung function, which may reduce the 
survival of CF patients. Such infections may also 
increase morbidity and mortality following lung 
transplantation (6-8). Patients infected with Bcc 
may develop a severe condition characterized by 
a fulminating pneumonic illness sometimes as-
sociated with septicemia, known as “cepacia 
syndrome”, which is related to high mortality (9). 
Although Bcc is found in soil and water, patient-
to-patient spread among CF patients has been 
reported for all the Bcc species; hence, the im-
portance of a strict segregation of infected pa-
tients (10-12). Intrinsic and acquired antibiotic 
resistance is considered to be a characteristic of 
Bcc. All Bcc strains are resistant to polymyxin B, 
and there are only a few antimicrobials effective 
against Bcc infections (13,14). Although B. 
cenocepacia has been considered the most 
common species, Bcc species prevalence may 
vary among different CF centers (15-17). 
Based on the importance of patient segre-
gation and on the different prognosis of infected 
CF patients, the identification of Bcc and its spe-
cies has been considered very important (18). 
The identification of Bcc is problematic and mis-
identification is common as Bcc is easily con-
fused with other non-fermentative Gram-
negative bacteria (4). Furthermore, because of 
the taxonomic complexity of these bacteria and 
the similarity of the species, the identification of 
individual Bcc species based on phenotypic 
methods is often a challenge (13,19). The mo-
lecular procedure polymerase chain reaction-
restriction fragment length polymorphism (PCR-
RFLP) based on the recA gene has been de-
scribed as one of the most reliable methods for 
the identification of Bcc species (20-22). 
The aims of the present study were to vali-
date the PCR-RFLP and to establish the preva-
lence of Bcc species and their susceptibility pro-
file among CF patients seen at a university hos-
pital in southern Brazil (Hospital de Clínicas de 




To analyze the prevalence of the species, 
we considered all patients seen at the HCPA 
from February to December 2006. We studied 
1,238 isolates from 244 patients (one to 20 for 
each patient). Isolates that met the inclusion 
criteria (80 isolates) were selected for the study. 
 
Inclusion criteria 
All bacteria isolated from respiratory mate-
rial of CF patients that grew in B. cepacia selec-
tive agar medium (BCSA-Oxoid
®
) supplemented 
with Burkholderia cepacia Selective Supplement 
(Oxoid
®
) which proved to be resistant to po-
lymyxin (disc with 300U) and were negative for 
pyrrolidonyl arylamidase (PYR) were selected for 
the PCR-RFLP.  
 
Bacterial reference strains 
Strains belonging to the different Bcc ge-
nomovars I to VIII used to validate the PCR-
RFLP technique were obtained from the Health 
Protection Agency, London, UK. 
 
Phenotypic identification 
A total of 77 isolates that met the inclusion 
criteria were also submitted to phenotypic identi-
fication using the API-20NE system 
(Biomerieux
®
) in accordance with the manufac-
turer's protocol. We considered as unequivocal 
identification by the API system all results show-
ing 99.9% of likelihood percentage. Moreover, 
we considered the identification of B. cepacia by 
the API system as comparable to the identifica-
tion of Bcc by PCR. 
 
Preparation of template DNA from bacterial 
cultures 
Fresh cultures of the bacterial isolates were 
suspended in 500 µL of TE buffer, heated to 80 
°C for 20 minutes and immediately frozen. After 
20 minutes, the suspension was thawed and 
centrifuged at 11,000 g for 4 minutes. Super-
natants containing the bacterial genomic DNA 
were collected and stored at 2 to 8 °C. The 
presence of DNA in the supernatants was con-
firmed by electrophoresis in 0.7% (wt/vol) aga-
rose gels (Life Technologies GIBCO BRL Prod-
ucts
®
) and the quantity and purity of DNA were 
assessed at 260 and 280 nm. 
 
PCR analysis 
A PCR with a specific primer for the recA 
gene was used to identify the Bcc. The Bcc recA 
gene (1,043 bp) was amplified using primers 
BCR1 (5’TGACCGCCGAGAAGAGCAA3’) and 
BCR2 (5’CTCTTCTTCGTCCATCGCCTC3’). 
Approximately 20 ng of DNA was transferred to 
a tube with 50 µL of reaction mix containing 1 U 
Taq DNA polymerase, 250 µM (each) deoxynu-
Leite FC et al  
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cleoside triphosphate, 1.5 mM MgCl2, and 1X 
PCR buffer. Approximately 20 pmol of each 
primer was added to reaction mix plus DNA and 
amplification was carried out using a Termo 
Techne TC-300 Barloworld Scientific. Speci-
mens were initially heated at 96 °C for 3 minutes 
before amplification using 35 cycles consisting of 
1 minute of denaturation at 96 °C, 1 minute of 
annealing at 56 °C, and 1.5 minute of extension 
at 72 °C. PCR was completed with a final exten-
sion step at 72 °C for 10 minutes.  
 
RFLP analysis of the Bcc recA gene 
Bcc recA amplicons were digested with 
HaeIII (Amersham-Pharmacia Biotech, St. Al-
bans, England) and MnlI (New England Biolabs 
Inc., Hitchin, England) restriction endonucleases. 
Amplicons (5 µL) were mixed with the endonu-
clease and its appropriate enzyme buffer, in 
accordance with the manufacturer’s instructions 
and incubated at 37 °C for 2 hours (22). 
 
Detection of PCR and RFLP products 
PCR-amplified products and the restriction 
fragments were analyzed by electrophoresis in 
2% (wt/vol) agarose gels. Molecular size mark-
ers (100-bp ladder; Life Technologies GIBCO 
BRL Products
®
) were used in all gels. DNA 
products were stained with ethidium bromide 
and viewed under UV light. 
 
Antibiotic resistance 
The disc diffusion susceptibility testing was 
performed to compare the results among the 
different species of B. cepacia. The technique 
was performed in accordance with the Clinical 
and Laboratory Standards Institute (CLSI) (23) 
and the results were classified as “Resistant”, 
“Intermediate” and “Susceptible” according to the 
CLSI criteria used for P. aeruginosa for the fol-
lowing antibiotics (Oxoid
®
): amikacin, aztreonam, 
cefepime, ciprofloxacin, doxycycline, chloram-
phenicol, gentamicin, imipenem, ticarcillin-
clavulanate, tobramycin, and piperacillin-
tazobactam. The antibiotics ceftazidime, mero-
penem, and trimethoprim-sulfamethoxazole were 




Comparison of the antibiotic resistance 
among genomovars was performed using the 
Fisher’s exact test. The SPSS 12.0 was used for 
statistical analysis. A P-value ≤ 0.05 was con-
sidered statistically significant for the majority of 
the comparisons. The Bonferroni correction (i.e., 
P < 0.0036) was also used for a few compari-




Of the 77 isolates submitted to API-20NE 
identification, 37 were identified as Burkholderia 
cepacia, two were Pseudomonas fluorescens, 
two were Oligella sp, one was Alcaligenes xy-
losoxidans, and one was Bordetella bronchisep-




PCR primers BCR1 and BCR2 amplified a 
single 1kb-amplicon from 66/80 isolates that met 
the inclusion criteria. 
 
PCR-RFLP for Bcc species 
The analysis of RFLP patterns generated 
by digestion with HaeIII and MnlI was capable of 
discriminating all eight species of the reference 
strains, including the subgroups IIIA and IIIB. 
Therefore, we considered that this method was 
validated to be used for the isolates included in 
this study. It is worth noting, however, that RFLP 
by MnlI was not able to distinguish Burkholderia 
ambifaria (VII) from Burkholderia anthina (VIII). 
These species were discriminated only by HaeIII 
PCR-RFLP (Figure 1). 
 
 
Figure 1 - RFLP analysis of the recA gene amplified from 
strains of B. cepacia (I), B. multivorans (II), B. cenocepacia 
IIIA, B. cenocepacia IIIB, B. stabilis (IV), B. vietnamiensis 
(V), B. dolosa (VI), B. ambifaria (VII) and B. anthina (VIII).  
A: HaeIII RFLP analysis. B: MnlI RFLP analysis. Ma: mo-
lecular size marker (100-bp ladder). C: negative control. 
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Correlation of phenotypic and genotypic 
identification 
Of the 37 isolates identified as B. cepacia 
by API-20NE, 34 were confirmed by PCR. Two 
isolates, from the same patient, were identified 
as Pseudomonas fluorescens by API-20NE and 
proved to be B. vietnamiensis by the molecular 
method. The bacteria identified by API-20NE as 
Oligella sp, Alcaligenes xylosoxidans and Borde-
tella bronchiseptica were negative for Bcc by 
PCR. Three isolates were identified by API-
20NE as belonging to Bcc and were negative by 
PCR. 
 
Prevalence of Bcc genomovars among CF 
isolates 
Of the 66 isolates which were PCR positive 
for Bcc, 40 were identified as B. cenocepacia (31 
IIIA and 9 IIIB), 12 as B. multivorans, four as B. 
vietnamiensis, and six as B. anthina. We were 
not able to identify the species of four isolates by 
PCR-RFLP (Table 1). 
 
Table 1 - Distribution of species among 66 Bcc iso-










B. cepacia 0 0 
B. multivorans 12 (18.1) 4 (15.4) 
B. cenocepacia 40 (60.6) 16 (61.5) 
Subgroup IIIA 31 (77.5) 12 (75.0) 
Subgroup IIIB 9 (22.5) 6 (37.5) 
B. stabilis 0 0 
B. vietnamiensis 4 (6.1) 2 (7.7) 
B. dolosa 0 0 
B. ambifaria 6 (9.1) 2 (7.7) 
B. anthina 0 0 
B. pyrrocinia 0 0 
B. ubonensis 0 0 
Not determined by PCR 4 (6.1) 2 (7.7) 
a
 Number of isolates belonging to a specific species (as 
percentage of the 66 isolates examined). 
b
 Number of patients infected with a specific Bcc species (as 
percentage of the 26 patients examined). The sum of the 
percentage of patients infected with the different genomovars 
IIIA and IIIB exceeds 100% since two patients were infected 
with both genomovars. 
 
The prevalence of Bcc among CF patients 
was established as we were able to identify 34 
patients with isolates that met the inclusion crite-
ria. Among these, eight patients had isolates that 
were negative for Bcc by PCR and two patients 
had isolates that were positive for Bcc but were 
not identified to species level by PCR-RFLP. 
Therefore, only 24 patients had isolates that 
were identified to Bcc species level. The species 
distribution among these 24 patients was as 
follows: 14 patients were colonized with B. ceno-
cepacia (10 patients with Bcc IIIA and four with 
Bcc IIIB), four patients were positive for B. mul-
tivorans, two for B. vietnamiensis, two for B. 
ambifaria, and two patients were positive for 
both B. cenocepacia IIIA and IIIB in different 
isolates (Table 1). 
Considering the total population of CF pa-
tients which had respiratory material submitted 
for bacteriological culture (244 patients), the 
prevalence of Bcc in CF was only 10.6% 
(26/244). 
 
Longitudinal distribution among CF patients 
We were able to evaluate 26 patients with 
more than one isolate and 24 of them proved to 
be colonized with the same Bcc species. It is 
worth noting that two patients had isolates be-
longing to the genomovar III (B. cenocepacia) 
which were subdivided into types IIIA and IIIB. 
Isolates from two patients were not identified to 
species level. 
 
Antibiotic resistance profile 
We compared each species with all the 
other species identified in this study according to 
their antibiotic resistance. B. multivorans proved 
to be more resistant to cefepime (P =0.005), 
piperacillin-tazobactam (P =0.012), chloram-
phenicol (P = 0.003), and imipenem (P <0.001). 
Conversely, all B. multivorans were susceptible 
to doxycycline (P =0.029). B. cenocepacia IIIA 
was more susceptible than the other species to 
cefepime (P =0.005), doxycycline (P =0.029), 
trimethoprim-sulfamethoxazole (P =0.040), 
piperacillin-tazobactam (P = 0.012), chloram-
phenicol (P =0.003), and imipenem (P <0.001). 
B. cenocepacia IIIB and B. vietnamiensis did not 
display statistical difference of antibiotic profile in 
relation to the others. B. ambifaria proved to be 





Bcc infection may be associated with an 
accelerated decline in pulmonary function and, 
therefore, it is extremely important to identify Bcc 
accurately in the CF pulmonary material. As Bcc 
may be transmissible among CF patients, it 
seems obvious that it is important to segregate 
Bcc-positive from Bcc-negative CF patients, 
considering their expected prognosis. Moreover, 
it has been described that B. cenocepacia is 
linked to an even more rapid progression of lung 
failure in CF patients and this leads to a need for 
species identification (10,11,24). 
Bcc has a complex taxonomic organization and 
its identification is a challenge for microbiology 
laboratories. In the present study, 77/80 isolates 
were submitted to both API-20NE and PCR-
RFLP identification and only 34 (44%) were 
identified as belonging to Bcc (or B. cepacia in 
Leite FC et al  
 
 
Rev HCPA 2011;31(2) 142 
the case of API-20NE) by both methods. Accord-
ing to these results, the API-20NE system 
proved to be relatively reliable for Bcc identifica 
tion (considering the identification of B. cepacia 
as Bcc). However, it was not able to distinguish 
among Bcc species. 
 
 
Table 2 - Percentage of antibiotic resistance among the main Bcc species (genomovars) from CF patients. 
 II IIIA IIIB V VII P-value 
AMK 10(100%) 31(100%) 8(100%) 3(75%) 6(100%) 0.068 





5(62.5%) 0 3(50%) 0.005 
CAZ 4(40%) 2(6.5%) 1(11.1%) 0 0 0.075 


















2(50%) 0 1(50%) <0.001 
MEM 4(44.4%) 4(12.9%) 2(22.2%) 0 1(16.7%) 0.265 
SXT 7(77.8%) 7(30.4%)
* 
5(71.4%) 1(50%) 4(80%) 0.040 
TIM 10(100%) 23(74.2%) 7(87.5%) 3(75%) 6(100%) 0.260 





2(25%) 1(25%) 1(25%) 0.012 
II: B. multivorans, IIIA: B. cenocepacia IIIA, IIIB: B. cenocepacia IIIB, IV: B. stabilis, V: B. vietnamiensis, VI: B. dolosa, VII: B. 
ambifaria, VIII: B. anthina, AMK: Amikacin; ATM: Aztreonam; FEP: Cefepime; CAZ: Ceftazidime; CIP: Ciprofloxacin; DOX: 
Doxycycline; CHL: Chloramphenicol; GEN: Gentamicin; IPM: Imipenem; MEM: Meropenem; SXT: Trimethoprim-
Sulfamethoxazole; TIM: Ticarcillin-Clavulanate; TOB: Tobramycin; TZP: Piperacillin-Tazobactam  P < 0.05 
+ 
P < 0.0036 
 
Conversely, this phenotypic method was 
not capable of discriminating 34 (44%) of the 
isolates. Therefore, a variety of Bcc isolates (as 
established by PCR) was not identified by the 
API system. As the molecular identification by 
PCR is superior to the biochemical identification 
procedures, this commercial phenotypic identifi-
cation does not seem to be suitable for identifi-
cation, especially when it provide negative re-
sults for B. cepacia. Hence, in order to identify 
the species (or genomovars) within the Bcc 
complex, a molecular method needs to be used 
(19,25). 
PCR Bcc investigation is based on the 
polymorphism of the recA gene. This gene en-
codes the recA, a multifunctional protein respon-
sible for DNA repair. The recA specific primers, 
used in the PCR method, are highly specific for 
Bcc members (22). In the present study, we 
initially used the amplification of the recA gene 
with primers BCR1 and BCR2 to classify Bcc 
isolates. Further, RFLP was performed with re-
striction endonucleases HaeIII and MnlI in order 
to identify the specific species/genomovar. The 
PCR-RFLP procedure is fast, sensitive, specific, 
reproducible, and appears to be a more reliable 
tool to discriminate Bcc species (25). In the pre-
sent study, this technique was capable of identi-
fying 66 isolates as belonging to Bcc and it dis-
criminated its species from I to VIII for 93.9% of 
the Bcc positive isolates. One reason that could 
explain the fact that a few species could not be 
identified by PCR-RFLP is that there are other 
Bcc species which were not evaluated in our 
study. Another reason is that there is no consis-
tent data in the literature regarding small varia-
tions in the PCR-RFLP patterns (26,27). 
During the study period, 10.6% (26/244) of 
CF patients that met the inclusion criteria were 
colonized with Bcc. Molecular analysis of the 
recA gene showed that B. cenocepacia followed 
by B. multivorans were the most common Bcc 
species in our CF population and all patients 
were colonized with only a single species. This 
predominance of B. cenocepacia and B. mul-
tivorans in CF patients has also been reported in 
most countries. In Australia and New Zealand, B. 
cenocepacia and B. multivorans were more fre-
quently encountered and accounted for a total of 
75% of the isolates. B. cenocepacia accounts for 
45.7% and B. multivorans for 29.3%, followed by 
B. cepacia (11.2%) (28). 
The prevalence of B. cenocepacia found in 
our CF center was also observed in a variety of 
other countries. B. cenocepacia is prevalent in 
CF centers in Portugal (15), Italy (16,29,30), 
Canada (31), Ireland (32), and Czech Republic 
(33). The Bcc species distribution in French CF 
centers is slightly different from all these coun-
tries, where B. multivorans is the most prevalent 
(51%), followed by B. cenocepacia (45%) (17). 
We understand that only a few antibiotics 
are standardized to be tested for Bcc. However, 
in our study, we evaluated a variety of antibiotics 
in order to obtain a comparison of results among 
all species. We found that the antimicrobial re-
Molecular identification of Burkholderia cepacia 
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sistance to the antibiotics tested varied greatly 
among Bcc species. As previously mentioned, 
we had to use a P value adjusted to a small 
number of isolates (P <0.0036). Therefore, B. 
multivorans was more resistant to chlorampheni-
col and imipenem; similarly, B. ambifaria was 
found to be markedly resistant to chlorampheni-
col. Conversely, B. cenocepacia IIIA was less 
resistant to these antibiotics. Among the antibiot-
ics standardized for Bcc (ceftazidime, mero-
penem and trimethoprim-sulfamethoxazole), only 
trimethoprim-sulfamethoxazole showed statisti-
cal significance (P <0.05) to be more effective 
for B. cenocepacia IIIA. We understand that, 
regardless the antibiotics approved by the CLSI, 
it may be important to evaluate other antibiotics 
for Bcc as the clinical treatment of the CF pa-
tients frequently requires different antibiotics 
from those standardized by the CLSI. 
The present study demonstrates the appli-
cation of a molecular method based on the 
polymorphism of the recA gene to identify Bcc 
species. It also provides an overview of the 
prevalence, distribution, and bacterial resistance 
of Bcc species at a CF center in southern Brazil. 
Our results confirmed that B. cenocepacia is the 
most prevalent species among CF patients. 
In conclusion, the phenotypic methods 
based on biochemical analysis proved not to be 
appropriate for the identification of Bcc. There-
fore, the use of a molecular technique is crucial 
for microbiology laboratories that process speci-
mens from CF patients. As we have demon-
strated, PCR-RFLP showed to be an unequivo-
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